Epcoritamab

Buy Epcoritamab (Tepkinly / Epkinly) Online in India
Generic Name/API:Epcoritamab-bysp
Packaging:Tepkinly / Epkinly is a clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous injection. It is available as a single-dose vial per carton in the following strengths: 4 mg/0.8 mL, 48 mg/0.8 mL.
Storage:Store in the refrigerator at 2° to 8°C (36°F to 46°F).
Dosage:For dosage information, please visit the General Information section.
Strength:Injection:4 mg/0.8 mL, 48 mg/0.8 mL in a single-dose vial
Indication:Tepkinly / Epkinly is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and in relapsed or refractory follicular lymphoma (FL).

Tepkinly / Epkinly (Epcoritamab) is a bispecific CD20-directed CD3 T-cell engager indicated for the following:

  1. Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. 
  2.  In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). 
  3. As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. 

Strength:

Injection: 4 mg/0.8 mL, 48 mg/0.8 mL in a single-dose vial.

Dosage: 

DLBCL and High-grade B-cell Lymphoma

Cyclea Day of treatment Dose of Tepkinly / Epkinly
Cycle 1
1 Step-up dose 1 0.16 mg
8 Step-up dose 2 0.8 mg
15 First full dose 48 mg
22 48 mg
Cycles 2 and 3 1, 8, 15 and 22 48 mg
Cycles 4 to 9 1 and 15 48 mg
Cycle 10 and beyond 1 and 15 48 mg

aCycle = 28 days

Tepkinly / Epkinly as Monotherapy for FL

Cyclea Day Dose of Tepkinly / Epkinly
Cycle 1
1 Step-up dose 1 0.16 mg
8 Step-up dose 2 0.8 mg
15 Step-up dose 3 3 mg
22 First full dose 48 mg
Cycles 2 and 3 1, 8, 15 and 22 48 mg
Cycles 4 to 9 1 and 15 48 mg
Cycle 10 and beyond 1 and 15 48 mg

aCycle = 28 days

Tepkinly / Epkinly in combination with Lenalidomide and Rituximab for FL

Cyclea Day Dose of Tepkinly / Epkinly
Cycle 1
1 Step-up dose 1 0.16 mg
8 Step-up dose 2 0.8 mg
15 Step-up dose 3 3 mg
22 First full dose 48 mg
Cycles 2 and 3 1, 8, 15 and 22 48 mg
Cycles 4 to 12 1 48 mg

aCycle = 28 days

Adverse effects:

  • Cytokine Release Syndrome (CRS)
  • Injection site reactions, 
  • Fatigue, musculoskeletal pain,
  • Fever, 
  • Diarrhea
  • COVID-19
  • Rash 
  • Abdominal pain. 

Storage:

Store refrigerated at 2°C to 8°C (36°F to 46°F). Keep in the original carton to protect from light. Do not freeze. Do not shake. 

Cytokine Release Syndrome (CRS): The most common symptoms of CRS are pyrexia, hypotension, hypoxia, dyspnea, chills, and tachycardia. Concurrent neurological adverse reactions included headache, confusional state, tremors, dizziness, and ataxia. 

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): The most common symptoms of ICANS are confusional state, lethargy, tremor, dysgraphia, aphasia, and non-convulsive status epilepticus. ICANS are not limited to these symptoms alone.

Infections: Epkinly can cause infections such as pneumonia, COVID-19, opportunistic infections and upper respiratory infections. The most common opportunistic infections of any grade were Cytomegalovirus (CMV) infection and herpesvirus infection. 

Cytopenias: Epkinly can cause serious or severe cytopenias, including neutropenia, lymphopenia, anemia, and thrombocytopenia.

Process to Import Tepkinly / Epkinly (Epcoritamab)

FAQ

Tepkinly / Epkinly (Epcoritamab) is a prescription medicine used to treat adults with:

  • certain types of DLBCL or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory),after 2 or more treatments.
  • Follicular lymphoma that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab.
  • Follicular lymphoma that has come back or that did not respond after 2 or more treatments. It is not known if EPKINLY is safe and effective in children.

Tepkinly / Epkinly is a bispecific CD20-directed CD3 T-cell engager that binds simultaneously with CD3 (present on T cells) and CD20 (present on the B lineage lymphoma and on the B-cells). This binding helps in activating T cells. T cells release toxic chemicals and proinflammatory cytokines that induce death of CD20+ B cells.

The most common side effects of Tepkinly / Epkinly (Epcoritamab) when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash and stomach area (abdominal pain).

The most common severe abnormal laboratory test results with Epkinly when used alone in DLBCL or highgrade B-cell lymphoma or FL include decreased white blood cells, decreased red blood cells, and decreased platelets.

The most common side effects of EPKINLY when used together with lenalidomide and rituximab in follicular lymphoma include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19 and fever

It is given by subcutaneous injection. The dosing schedule depends on the condition being treated.

While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certificate and possesses a valid operating license. These credentials confirm the suppliers adherence to International standards for the proper distribution of medicinal products.

The cost of Tepkinly / Epkinly (Epcoritamab) varies as it’s not approved in India and must be imported. Factors like international currency exchange rates (USD/EUR), import duties, and supplier availability influence the final price. For the latest pricing and details, please contact 24/7 QualityMeds.

To Buy Epcoritamab (Tepkinly / Epkinly) Online in India at a genuine price, contact 24/7QualityMeds. We assist you in importing this medication legally and at the best possible cost.